{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:50Z","timestamp":1789516670177,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:00:00Z","timestamp":1440633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.nefro.2015.07.005","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T03:38:59Z","timestamp":1445225939000},"page":"421-447","source":"Crossref","is-referenced-by-count":157,"title":["Actualizaci\u00f3n en s\u00edndrome hemol\u00edtico ur\u00e9mico at\u00edpico: diagn\u00f3stico y tratamiento. Documento de consenso"],"prefix":"10.1016","volume":"35","author":[{"given":"Josep M.","family":"Campistol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Griny\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mac\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mendiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Vilalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodr\u00edguez de C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2015.07.005_bib0745","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib0750","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib0755","unstructured":"Alexion Pharmaceuticals I. Soliris (eculizumab). Ficha t\u00e9cnica 2012."},{"key":"10.1016\/j.nefro.2015.07.005_bib0760","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0765","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib0770","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2015.07.005_bib0775","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib0780","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: Incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.nefro.2015.07.005_bib0785","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mop.0000152997.66070.e9","article-title":"Hemolytic uremic syndrome: Pathogenesis, treatment, and outcome","volume":"17","author":"Siegler","year":"2005","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.nefro.2015.07.005_bib0790","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1542\/peds.2005-0785","article-title":"Predictors of fatality in postdiarrheal hemolytic uremic syndrome","volume":"117","author":"Oakes","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.nefro.2015.07.005_bib0795","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0800","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0805","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib0810","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","article-title":"Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)","volume":"25","author":"Westra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib0815","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib0820","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib0825","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.07.005_bib0830","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nefro.2015.07.005_bib0835","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0840","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib0845","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib0850","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib0855","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0860","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-007-0604-1","article-title":"Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder","volume":"22","author":"Sharma","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0865","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience","volume":"151","author":"Waters","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.nefro.2015.07.005_bib0870","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-010-1690-z","article-title":"Pandemic H1 N1 influenza A infection and (atypical) HUS \u2014 more than just another trigger","volume":"26","author":"Allen","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0875","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.07.005_bib0880","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1055\/s-0030-1262881","article-title":"Treatment of typical (enteropathic) hemolytic uremic syndrome","volume":"36","author":"Bitzan","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nefro.2015.07.005_bib0885","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0890","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2015.07.005_bib0895","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2015.07.005_bib0900","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib0905","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.nefro.2015.07.005_bib0910","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib0915","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib0920","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: Causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib0925","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/adc.76.6.518","article-title":"Heterogeneity of atypical haemolytic uraemic syndromes","volume":"76","author":"Neuhaus","year":"1997","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.nefro.2015.07.005_bib0930","first-page":"5","article-title":"Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0935","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS","volume":"25","author":"Sallee","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib0940","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0945","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s004670050058","article-title":"Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes","volume":"14","author":"Kaplan","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0950","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0955","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.ajkd.2013.09.020","article-title":"Skin involvement in atypical hemolytic uremic syndrome","volume":"63","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib0960","series-title":"Complement","author":"Law","year":"1995"},{"key":"10.1016\/j.nefro.2015.07.005_bib0965","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1681\/ASN.V122297","article-title":"The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in Short Consensus Repeat 20","volume":"12","author":"Caprioli","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0970","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib0975","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2005101051","article-title":"Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome","volume":"17","author":"Fremeaux-Bacchi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0980","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fremeaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib0985","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nefro.2015.07.005_bib0990","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib0995","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2015.07.005_bib1000","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/318201","article-title":"Clustering of missense mutations in the C-terminal region of factor h in atypical hemolytic uremic syndrome","volume":"68","author":"P\u00e9rez-Caballero","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib1005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/318203","article-title":"Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition","volume":"68","author":"Richards","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib1010","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nefro.2015.07.005_bib1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","article-title":"Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor H","volume":"151","author":"De Cordoba","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1025","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib1030","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib1035","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nefro.2015.07.005_bib1040","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.molimm.2005.11.008","article-title":"Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree","volume":"43","author":"Esparza-Gordillo","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1045","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1060","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u025b-associated atypical hemolytic uremic syndrome","volume":"9","author":"Sanchez-Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1070","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1075","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation","volume":"27","author":"Zuber","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.nefro.2015.07.005_bib1085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","article-title":"Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation","volume":"26","author":"Al-Akash","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1090","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1095","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1100","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib1105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1600-6143.2009.02586.x","article-title":"Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome","volume":"9","author":"Le Quintrec","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1110","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ndt\/gfn687","article-title":"Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria","volume":"24","author":"De Serres","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.10450","article-title":"Morphologic diagnosis of thrombotic thrombocytopenic purpura","volume":"75","author":"Burns","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ccc.2005.02.001","article-title":"Disseminated intravascular coagulation: What's new?","volume":"21","author":"Levi","year":"2005","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.nefro.2015.07.005_bib1125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3324\/haematol.11196","article-title":"Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: Much progress and many remaining issues","volume":"92","author":"Mannucci","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.nefro.2015.07.005_bib1130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00277-009-0707-9","article-title":"Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment","volume":"88","author":"Alvarez-Larran","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1140","article-title":"Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group","volume":"144","author":"Contreras","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefro.2015.07.005_bib1145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nefro.2015.07.005_bib1150","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1160","first-page":"458","article-title":"A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab","volume":"2","author":"Lionet","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.nefro.2015.07.005_bib1165","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","article-title":"Complications of apheresis in children","volume":"47","author":"Michon","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.nefro.2015.07.005_bib1170","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1175","first-page":"822A","article-title":"Eculizumab (ECU) in atypical Hemolytic Uremic Syndrome (aHUS) Patients (Pts) with long disease duration and Chronic Kidney Disease (CKD): Sustained efficacy at 3 years","volume":"24","author":"Delmas","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1180","first-page":"822A","article-title":"Eculizumab (ECU) maintains efficacy in atypical Hemolytic Uremic Syndrome (aHUS) Patients (Pts) with progressing Thrombotic Microangiopathy (TMA): 3-year (Yr) update","volume":"24","author":"Gaber","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1220","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1225","first-page":"49","article-title":"Eculizumab (ECU) inhibits Thrombotic Microangiopathy (TMA) and improves renal function in adult atypical Hemolytic Uremic Syndrome (aHUS) patients (Pts)","volume":"24","author":"Fakhouri","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1190","first-page":"821A","article-title":"Eculizumab (ECU) inhibits Thrombotic Microangiopathy (TMA) and improves renal function in pediatric atypical Hemolytic Uremic Syndrome (aHUS) patients (Pts)","volume":"24","author":"Greenbaum","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1230","first-page":"473","article-title":"Reduction of biomarkers related to thrombotic microangiopathy in patients with aHUS treated with eculizumab","volume":"99","author":"Faas","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.nefro.2015.07.005_bib1235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1240","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrneph.2013.150","article-title":"Thrombotic microangiopathy: Eculizumab for atypical haemolytic uraemic syndrome: What next?","volume":"9","author":"Fakhouri","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: An analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1215","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: A report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2421.2421","article-title":"Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab","volume":"114","author":"Legault","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib1255","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","article-title":"Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation","volume":"55","author":"Davin","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndtplus\/sfr107","article-title":"Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic uremic syndrome","volume":"5","author":"Dur\u00e1n","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2015.07.005_bib1265","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1270","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-6143.2007.02029.x","article-title":"Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H","volume":"8","author":"Jalanko","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2215\/CJN.02170508","article-title":"Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome","volume":"4","author":"Saland","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1280","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/j.1600-6143.2010.03228.x","article-title":"Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H","volume":"10","author":"Haller","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1285","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.ajkd.2011.04.008","article-title":"Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H","volume":"58","author":"Wilson","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1290","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00467-013-2630-5","article-title":"Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation","volume":"29","author":"Tran","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1295","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00467-009-1188-8","article-title":"Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome","volume":"24","author":"Davin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1300","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1305","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1310","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","article-title":"Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome","volume":"6","author":"Nester","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1315","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","article-title":"Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein","volume":"12","author":"Krid","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1320","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00467-013-2591-8","article-title":"Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH\/CFHR1 hybrid gene","volume":"29","author":"Roman-Ortiz","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1325","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/TP.0b013e31829d388d","article-title":"Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation","volume":"96","author":"Blasco Pelicano","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2015.07.005_bib1330","doi-asserted-by":"crossref","DOI":"10.1053\/ajkd.2002.36938","article-title":"Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor","volume":"40","author":"Donne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1340","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1345","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1600-6143.2003.00051.x","article-title":"Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage","volume":"3","author":"Robson","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1350","first-page":"S1","article-title":"The successful treatment of transplant-associated thrombotic microangiopathy with eculuzimab P632","volume":"47","author":"Murphy","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1355","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation \u2014 a case report","volume":"43","author":"Chandran","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2015.07.005_bib1360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo post-transplantation thrombotic microangiopathy: A case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1365","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","author":"Peffault de Latour","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1370","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1375","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4682.4682","article-title":"Long-term outcome in a pediatric patient with atypical hemolytic uremic syndrome (aHUS) with sustained eculizumab (ECU) treatment","volume":"118","author":"Gruppo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2015.07.005_bib1380","first-page":"988 A","article-title":"Eculizumab treatment for aHUS in a child with positive family history","volume":"20","author":"Fremont","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1385","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1390","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"Kose","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nefro.2015.07.005_bib1395","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00467-010-1719-3","article-title":"Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome","volume":"26","author":"Lapeyraque","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1400","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ajh.21862","article-title":"Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome","volume":"85","author":"Prescott","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1405","first-page":"45","article-title":"Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): An update on a previous case report","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1410","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","article-title":"Eculizumab in atypical hemolytic uremic syndrome: Long-term clinical course and histological findings","volume":"26","author":"Tschumi","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1415","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00467-012-2130-z","article-title":"Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count","volume":"27","author":"Dorresteijn","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1420","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ndtplus\/sfr174","article-title":"Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis","volume":"5","author":"Kim","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2015.07.005_bib1425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndtplus\/sfr157","article-title":"Early treatment with eculizumab in atypical haemolytic uraemic syndrome","volume":"5","author":"Garjau","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2015.07.005_bib1430","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/j.ajkd.2011.11.027","article-title":"Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants","volume":"59","author":"Ariceta","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2015.07.005_bib1435","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1440","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1445","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000357520","article-title":"A case of atypical hemolytic uremic syndrome successfully treated with eculizumab","volume":"3","author":"Thajudeen","year":"2013","journal-title":"Case Rep Nephrol Urol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1450","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1542\/peds.2012-0903","article-title":"Peripheral gangrene in children with atypical hemolytic uremic syndrome","volume":"131","author":"Malina","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.nefro.2015.07.005_bib1455","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1542\/peds.2011-1685","article-title":"Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: A case report","volume":"130","author":"Giordano","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.nefro.2015.07.005_bib1460","first-page":"326","article-title":"Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis","volume":"82","author":"Povey","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1465","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-012-1615-y","article-title":"Profound neurological injury in a patient with atypical hemolytic uremic syndrome","volume":"92","author":"Salem","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1470","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00467-013-2492-x","article-title":"Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B","volume":"28","author":"Gilbert","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1475","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","author":"Ardissino","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.nefro.2015.07.005_bib1480","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ckj\/sfs185","article-title":"Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice","volume":"6","author":"Delmas","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2015.07.005_bib1485","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","article-title":"Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab","volume":"159","author":"Zschiedrich","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1490","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2015.07.005_bib1495","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.transproceed.2010.09.125","article-title":"Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: Case report","volume":"42","author":"Chatelet","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2015.07.005_bib1500","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","article-title":"Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome","volume":"9","author":"Chatelet","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2015.07.005_bib1505","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","author":"Larrea","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2015.07.005_bib1510","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","author":"Alachkar","year":"2012","journal-title":"Transpl Int"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T13:29:49Z","timestamp":1692106189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699515001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0211699515001356"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2015.07.005","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}